Targeted Therapy / Oncology — Prostate Cancer

Abiraterone Acetate (abiraterone acetate)

Multiple manufacturers (generic); original brand: Zytiga by Janssen · CYP17 Inhibitor / Androgen Biosynthesis Inhibitor

FDA Approved 2011 Oral tablet Specialty Medication
Abiraterone Acetate Tablets 250mg bottles and blister pack, generic specialty pharmacy

What is Abiraterone Acetate? Abiraterone acetate is a CYP17 inhibitor that blocks androgen biosynthesis in the adrenal glands, testes, and tumor tissue. It is used with prednisone for metastatic castration-resistant prostate cancer (mCRPC) and metastatic high-risk castration-sensitive prostate cancer (mCSPC).

About Abiraterone Acetate

Brand NameAbiraterone Acetate
Generic / INNabiraterone acetate
Drug ClassCYP17 Inhibitor / Androgen Biosynthesis Inhibitor
ManufacturerMultiple manufacturers (generic); original brand: Zytiga by Janssen
AdministrationOral tablet
FDA Approval2011
📦 Available as 250 mg tablets (standard formulation — take on empty stomach) and 500 mg fine particle tablets (Yonsa — take with food). Formulations are NOT interchangeable on a mg-per-mg basis.

FDA-Approved Uses for Abiraterone Acetate

Indications are based on FDA approval. Your healthcare provider determines appropriate use based on your specific diagnosis, stage, biomarker status, and overall clinical picture.

  • Metastatic castration-resistant prostate cancer (mCRPC) — with prednisone
  • Metastatic high-risk castration-sensitive prostate cancer (mCSPC) — with prednisone or methylprednisolone
Biomarker Note: No biomarker testing is required for the approved indications, though AR splice variant testing (AR-V7) may inform treatment sequencing decisions in the mCRPC setting.

How Does Abiraterone Acetate Work?

Abiraterone acetate is converted in vivo to abiraterone, which inhibits CYP17 (17α-hydroxylase / C17,20-lyase) — a key enzyme in androgen biosynthesis in the adrenal glands, testes, and prostate tumor tissue. By blocking this enzyme, abiraterone reduces testosterone and other androgen levels below those achievable by castration alone. Must be used with a corticosteroid to prevent mineralocorticoid excess side effects.

Dosage & Administration

Standard abiraterone acetate (generic/Zytiga): 1000 mg orally once daily on an empty stomach (at least 1 hour before and 2 hours after eating), taken with prednisone 5 mg twice daily. Yonsa (fine particle formulation): 500 mg with food. Dose adjustments apply for hepatic impairment.

⚠️ Important

Dosing is individualized by the prescribing clinician. Never adjust your dose without consulting your healthcare provider. This information is educational only and does not replace the official prescribing information.

Warnings, Precautions & Side Effects

General Warning

Mineralocorticoid excess — hypertension, hypokalemia, fluid retention (manage with corticosteroid). Hepatotoxicity — monitor LFTs. Adrenocortical insufficiency (especially during stress). Cardiac disorders. Embryo-fetal toxicity (male patients must use contraception).

⛔ Serious Warnings & Precautions
  • Mineralocorticoid excess (hypertension, hypokalemia)
  • Hepatotoxicity
  • Adrenocortical insufficiency
  • Cardiac disorders (QT prolongation risk with some drug interactions)

Common Side Effects

  • Fatigue
  • Joint swelling/discomfort
  • Edema
  • Hot flush
  • Diarrhea
  • Urinary tract infection
  • Cough
  • Hypertension
  • Hypokalemia

This is not a complete list. Always report new or worsening symptoms to your healthcare provider promptly.

Storage & Handling

Store at room temperature 20°C to 25°C (68°F to 77°F). Keep in original container.

BiologicHealthPlus provides temperature-monitored cold-chain specialty delivery for medications requiring refrigeration. Never use a medication if its storage conditions have been compromised.

Insurance Coverage, Prior Authorization & Patient Assistance

🛡️ Commercial Insurance

Abiraterone Acetate is covered by most major commercial insurance plans when medically necessary and prior authorized. Coverage tier and cost-sharing vary by plan.

✅ Prior Authorization

Prior authorization is required by virtually all insurance plans for Abiraterone Acetate. BiologicHealthPlus handles the complete prior authorization process at no cost to patients or providers.

🏥 Medicare Coverage

Medicare Part D covers this oral specialty medication. Medicaid coverage varies by state.

🆓 Patient Assistance

Manufacturer patient assistance programs may be available for eligible uninsured or underinsured patients. Contact BiologicHealthPlus for a confidential eligibility review.

Prior Authorization Patient Assistance Insurance & Savings Medication Costs

Frequently Asked Questions — Abiraterone Acetate

Abiraterone acetate (brand name Zytiga; also available as generic) is used for metastatic castration-resistant prostate cancer (mCRPC) and metastatic high-risk castration-sensitive prostate cancer (mCSPC), always in combination with a corticosteroid like prednisone.

Abiraterone blocks CYP17, which reduces androgen levels but can cause a compensatory rise in ACTH, leading to mineralocorticoid excess (hypertension, fluid retention, low potassium). Co-administration with prednisone (a corticosteroid) suppresses ACTH and prevents these side effects.

The standard formulation (250 mg tablets) must be taken on an EMPTY stomach — at least 1 hour before and 2 hours after eating. Taking it with food significantly increases drug exposure and can cause serious adverse effects. The Yonsa formulation (500 mg) is taken WITH a low-fat meal.

Yes. Generic abiraterone acetate 250 mg tablets are widely available from multiple manufacturers. The original brand name is Zytiga (Janssen).

Generic abiraterone acetate is covered under Medicare Part D and most commercial insurance plans. Prior authorization is required. BiologicHealthPlus can assist with the prior authorization process.

Related Medications

Xtandi (enzalutamide)  ·  Erleada (apalutamide)  ·  Nubeqa (darolutamide)  ·  Docetaxel

Related Conditions

Metastatic castration-resistant prostate cancer (mCRPC)  ·  Castration-sensitive prostate cancer (mCSPC)  ·  Prostate cancer

Comparisons

Oncology

Authoritative References

Medical Disclaimer: This page is for general educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult your oncologist, hematologist, or licensed healthcare professional before making any treatment decisions. Last reviewed: August 2026 by the BiologicHealthPlus Clinical Team.